ReviewThe American journal of gastroenterology2010
Predictors of progression in Barrett's esophagus: current knowledge and future directions.
Review in The American journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett's Esophagus.Digestive diseases and sciences · 2016Pooled it
- Detection of Barrett's neoplasia with a near-infrared fluorescent heterodimeric peptide.Endoscopy · 2022Trial
- Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Trial
- Article
- Molecular biomarkers of progression from Barrett's esophagus to esophageal adenocarcinoma.Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Article
- Challenges in Determining the Role of Microbiome Evolution in Barrett's Esophagus and Progression to Esophageal Adenocarcinoma.Microorganisms · 2021Review
- Optimal Timing for Cancer Screening and Adaptive Surveillance Using Mathematical Modeling.Cancer research · 2021Article
- Is Malignant Potential of Barrett's Esophagus Predictable by Endoscopy Findings?Life (Basel, Switzerland) · 2020Review
- Signatures within the esophageal microbiome are associated with host genetics, age, and disease.Microbiome · 2018Article
- How Should We Report Endoscopic Results in Patient's with Barrett's Esophagus?Digestive diseases and sciences · 2018Review
- Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths.Translational oncology · 2018Article
- Endoscopic therapy for confirmed low-grade dysplasia in Barrett's esophagus.Translational gastroenterology and hepatology · 2018Review
- Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview.Annals of gastroenterology · 2017Review
- Esophageal Cancer Prevention.Gastroenterology & hepatology · 2016Article
- Low risk of adenocarcinoma and high-grade dysplasia in patients with non-dysplastic Barrett's esophagus: Results from a cohort from a country with low esophageal adenocarcinoma incidence.United European gastroenterology journal · 2016Article
- A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus.PLoS computational biology · 2016Article
- Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.Gastroenterology · 2015Article
- Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus.World journal of gastroenterology · 2015Review
- A Multiscale Model Evaluates Screening for Neoplasia in Barrett's Esophagus.PLoS computational biology · 2015Article
- Surveillance for low-grade dysplastic Barrett's oesophagus: one size fits all?World journal of surgery · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Barrett's esophagus (BE) is the strongest risk factor for esophageal adenocarcinoma (EAC), a malignancy with persistently poor long-term outcomes. EAC is thought to develop through progression of metaplasia to dysplasia to invasive carcinoma. Identification of factors predicting progression to EAC would help in focusing surveillance, chemoprevention, or ablation for those deemed to be at highest risk of progression. We performed a comprehensive review of the literature and summarized current evidence on risk factors for progression in subjects with known BE. Clinical and demographic factors (age, male gender, length of BE segment) are associated with modestly increased odds of progression to EAC in some studies. Biomarkers such as aneuploidy and p53 loss of heterozygosity have been associated with increased risk of progression to high-grade dysplasia and/or EAC in single-center prospective cohort studies. Promising newer techniques and markers have been recently reported with the potential to help risk stratify BE subjects. Development of a comprehensive BE risk progression score comprised of both clinical and biomarker variables should be the ultimate goal and can be achieved by multicenter prospective collaborative efforts. Although it would be challenging, creation of such a score has the potential to improve outcomes and make the management of patients with BE more cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.